Layla Zulfa

Empowering Progress: METAVIVOR Launches 2026 Grant Cycle Amidst a Landscape of Hope and Innovation empowering-progress-metavivor-launches-2026-grant-cycle-amidst-a-landscape-of-hope-and-innovation

empowering-progress-metavivor-launches-2026-grant-cycle-amidst-a-landscape-of-hope-and-innovation

Empowering Progress: METAVIVOR Launches 2026 Grant Cycle Amidst a Landscape of Hope and Innovation

Layla Zulfa May 9, 2026

By Editorial Staff As the medical community continues to push the boundaries of oncology, the quest for...

METAvivor Advocacy Update: Navigating the FY 2027 Budget and Strengthening the Metastatic Breast Cancer Voice metavivor-advocacy-update-navigating-the-fy-2027-budget-and-strengthening-the-metastatic-breast-cancer-voice

metavivor-advocacy-update-navigating-the-fy-2027-budget-and-strengthening-the-metastatic-breast-cancer-voice

METAvivor Advocacy Update: Navigating the FY 2027 Budget and Strengthening the Metastatic Breast Cancer Voice

Layla Zulfa May 8, 2026

As the first quarter of 2026 draws to a close, the METAvivor advocacy team is intensifying its...

Breakthrough in Pathology: New Molecular Markers Identified to Distinguish Between Rare Langerhans Cell Neoplasms breakthrough-in-pathology-new-molecular-markers-identified-to-distinguish-between-rare-langerhans-cell-neoplasms

breakthrough-in-pathology-new-molecular-markers-identified-to-distinguish-between-rare-langerhans-cell-neoplasms

Breakthrough in Pathology: New Molecular Markers Identified to Distinguish Between Rare Langerhans Cell Neoplasms

Layla Zulfa July 23, 2025

Main Facts: Solving a Diagnostic Dilemma Langerhans cell sarcoma (LCS) is an exceptionally rare, highly aggressive malignant...